SCHEMBL3552835

SCHEMBL3552835

O=C(Nc1cccc(F)c1)N1CC[N]CC1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
CYP2D6 P10635 5/20 0.62
NPC1 O15118 1/20 0.62
USP2 O75604 6/20 0.61
CYP2C19 P33261 4/20 0.61
CYP3A4 P08684 6/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
CYP1A2 P05177 1/20 0.60
POLB P06746 1/20 0.58
MAPT P10636 1/20 0.58
TRPV1 Q8NER1 1/20 0.57
ALOX15 P16050 1/20 0.55
FAAH O00519 2/20 0.55
CYP2C9 P11712 2/20 0.55
LMNA P02545 1/20 0.55
HIF1A Q16665 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419469 0.85 RAB9A (0.68) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL22218771 0.84 NPC1 (0.67) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL20236578 0.82 ALDH1A1 (0.62) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL5433044 0.82 LMNA (0.57) ALDH1A1USP2CYP2C19CYP3A4SMN1; SMN2
SCHEMBL4311734 0.82 KDM4E (0.68) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL654852 0.82 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2POLBMAPTFAAH
SCHEMBL20237020 0.82 SMN1; SMN2 (0.68) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL2403385 0.82 ALDH1A1 (0.76) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL22217924 0.81 ALDH1A1 (0.61) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL3723811 0.81 CYP2C9 (0.65) ALDH1A1CYP2D6NPC1USP2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 US disclosed
EP-2032140-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-03-11 EP disclosed
WO-2007138355-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 ALDH1A1 139/4885CYP2D6 3589/4885NPC1 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.